Boston Scientific Corporation
Shortcut
0.72Normalized diluted EPS
-0.1% vs Street
Street
0.72Normalized diluted EPS
October 25 consensus snapshot
Real
0.73Issuer adjusted diluted EPS
Model download
Explore the assumptions and calculations behind the forecast.
Shortcut’s reasoning.
Pre-incident run-rate built by business ~ $5.28bn, in line with the Jul-29 3Q26 guide (3-5% growth, $0.80-0.82 adj. EPS): base businesses ~+6%, U.S. WATCHMAN and U.S. EP down mid-single digits sequentially as guided.
Aug-25 cyber incident halted global manufacturing/shipping for ~8 days (CEO); operations fully restored Sep-9; company 8-K says Q3 guidance unlikely to be met. Model: 8/92 days lost x 45% not recaptured = ~3.9% (~$206m) net sales loss -> ~$5.07bn.
Drop-through: ~70% adjusted gross margin on lost sales plus ~$35m idle-plant/expedite cost, offset by ~$35m variable-cost flex; adj. op margin ~25.9% vs 28.4% in Q2; BTL $125m; 12% tax; 1,451m diluted shares -> $0.72 adj. EPS.
On the record.
- Reporting period
- Q3 2026 (FQ3 2026 - Sep 2026; quarter ended 2026-09-30)
- Reporting basis
- consensus normalized issuer adjusted diluted EPS, USD per common share
- Consensus snapshot
- October 25, 2026
- Model / effort
- Opus 5.5 · High effort
- Workbook
- Reviewed workbook
Record history
- Forecast generated
- Oct 26, 2026 at 2:55 PM PDT
- Reviewed revision completed
- Oct 26, 2026 at 2:55 PM PDT
- First published
- Oct 26, 2026 at 3:32 PM PDT
Result basis
Boston Scientific reports adjusted diluted EPS $0.73 and GAAP diluted EPS $0.40 for the quarter ended September 30, 2026. The issuer reconciliation and diluted common-share basis match the published adjusted convention.